KR101584925B1 - Pde10a 억제제로서의 트라이아졸로피리딘 화합물 - Google Patents
Pde10a 억제제로서의 트라이아졸로피리딘 화합물 Download PDFInfo
- Publication number
- KR101584925B1 KR101584925B1 KR1020147009588A KR20147009588A KR101584925B1 KR 101584925 B1 KR101584925 B1 KR 101584925B1 KR 1020147009588 A KR1020147009588 A KR 1020147009588A KR 20147009588 A KR20147009588 A KR 20147009588A KR 101584925 B1 KR101584925 B1 KR 101584925B1
- Authority
- KR
- South Korea
- Prior art keywords
- pyridin
- triazolo
- amide
- pyrazole
- carboxylic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- LKNPZFHEMLZXBD-UHFFFAOYSA-N Brc1c[n]2nc(N3CCCC3)nc2cc1 Chemical compound Brc1c[n]2nc(N3CCCC3)nc2cc1 LKNPZFHEMLZXBD-UHFFFAOYSA-N 0.000 description 1
- VJLFOZHHFFIUPZ-UHFFFAOYSA-N CCN(CC)C(c1c(C(Nc2c[n]3nc(N(CC)CC)nc3cc2)=O)[n](C)nc1)=O Chemical compound CCN(CC)C(c1c(C(Nc2c[n]3nc(N(CC)CC)nc3cc2)=O)[n](C)nc1)=O VJLFOZHHFFIUPZ-UHFFFAOYSA-N 0.000 description 1
- AEUCREGXZDKFAM-UHFFFAOYSA-N CCN(CC)c1n[n](cc(cc2)NC(c([n](C)nc3)c3C(N3CCCC3)=O)=O)c2n1 Chemical compound CCN(CC)c1n[n](cc(cc2)NC(c([n](C)nc3)c3C(N3CCCC3)=O)=O)c2n1 AEUCREGXZDKFAM-UHFFFAOYSA-N 0.000 description 1
- IFDPNXXBILVGEN-UHFFFAOYSA-N CN(C)c1n[n](cc(cc2)N)c2n1 Chemical compound CN(C)c1n[n](cc(cc2)N)c2n1 IFDPNXXBILVGEN-UHFFFAOYSA-N 0.000 description 1
- BFHHRKYKYJJHAB-UHFFFAOYSA-N CN(C)c1n[n](cc(cc2)NC(c([n](C)nc3)c3C(N3CCCC3)=O)=O)c2n1 Chemical compound CN(C)c1n[n](cc(cc2)NC(c([n](C)nc3)c3C(N3CCCC3)=O)=O)c2n1 BFHHRKYKYJJHAB-UHFFFAOYSA-N 0.000 description 1
- CEDLZPJJGASHED-UHFFFAOYSA-N C[n]1ncc(C(N(C2)CC2F)=O)c1C(Nc1c[n]2nc(N3CCOCC3)nc2cc1)=O Chemical compound C[n]1ncc(C(N(C2)CC2F)=O)c1C(Nc1c[n]2nc(N3CCOCC3)nc2cc1)=O CEDLZPJJGASHED-UHFFFAOYSA-N 0.000 description 1
- LVRYZQXSFIATTI-UHFFFAOYSA-N C[n]1ncc(C(N2CCOCC2)=O)c1C(Nc1c[n]2nc(-c3cnccc3)nc2cc1)=O Chemical compound C[n]1ncc(C(N2CCOCC2)=O)c1C(Nc1c[n]2nc(-c3cnccc3)nc2cc1)=O LVRYZQXSFIATTI-UHFFFAOYSA-N 0.000 description 1
- PUZVLELEFGWWPP-UHFFFAOYSA-N C[n]1ncc(C(N2CCOCC2)=O)c1C(Nc1c[n]2nc(N3CCCC3)nc2cc1)=O Chemical compound C[n]1ncc(C(N2CCOCC2)=O)c1C(Nc1c[n]2nc(N3CCCC3)nc2cc1)=O PUZVLELEFGWWPP-UHFFFAOYSA-N 0.000 description 1
- OUSRWXSPNFLGGF-UHFFFAOYSA-N C[n]1ncc(C(N2CCOCC2)=O)c1C(Nc1c[n]2nc(N3CCOCC3)nc2cc1)=O Chemical compound C[n]1ncc(C(N2CCOCC2)=O)c1C(Nc1c[n]2nc(N3CCOCC3)nc2cc1)=O OUSRWXSPNFLGGF-UHFFFAOYSA-N 0.000 description 1
- OXCUUSYKZUHXGF-UHFFFAOYSA-N Nc1c[n]2nc(N3CCCC3)nc2cc1 Chemical compound Nc1c[n]2nc(N3CCCC3)nc2cc1 OXCUUSYKZUHXGF-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11181752.4 | 2011-09-19 | ||
| EP11181752 | 2011-09-19 | ||
| PCT/EP2012/068203 WO2013041472A1 (en) | 2011-09-19 | 2012-09-17 | Triazolopyridine compounds as pde10a inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20140075716A KR20140075716A (ko) | 2014-06-19 |
| KR101584925B1 true KR101584925B1 (ko) | 2016-01-12 |
Family
ID=46851999
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020147009588A Expired - Fee Related KR101584925B1 (ko) | 2011-09-19 | 2012-09-17 | Pde10a 억제제로서의 트라이아졸로피리딘 화합물 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US8946427B2 (enExample) |
| EP (1) | EP2758396B1 (enExample) |
| JP (1) | JP2014526533A (enExample) |
| KR (1) | KR101584925B1 (enExample) |
| CN (1) | CN103827114B (enExample) |
| AU (1) | AU2012311713A1 (enExample) |
| BR (1) | BR112014006248A2 (enExample) |
| CA (1) | CA2846758C (enExample) |
| CL (1) | CL2014000641A1 (enExample) |
| CO (1) | CO6900144A2 (enExample) |
| EA (1) | EA201490599A1 (enExample) |
| ES (1) | ES2626801T3 (enExample) |
| IL (1) | IL231403A0 (enExample) |
| MX (1) | MX2014003025A (enExample) |
| PE (1) | PE20141553A1 (enExample) |
| PH (1) | PH12014500499A1 (enExample) |
| SG (1) | SG11201400759RA (enExample) |
| UA (1) | UA108711C2 (enExample) |
| WO (1) | WO2013041472A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2757882B1 (en) | 2011-09-22 | 2020-11-04 | Merck Sharp & Dohme Corp. | Imidazopyridyl compounds as aldosterone synthase inhibitors |
| EP2757883B1 (en) | 2011-09-22 | 2021-01-13 | Merck Sharp & Dohme Corp. | Triazolopyridyl compounds as aldosterone synthase inhibitors |
| DK2991984T3 (en) | 2013-04-30 | 2017-05-08 | Hoffmann La Roche | PALLADIUM-CATALYST COUPLING OF PYRAZOLAMIDES |
| TWI652014B (zh) | 2013-09-13 | 2019-03-01 | 美商艾佛艾姆希公司 | 雜環取代之雙環唑殺蟲劑 |
| CA2956268A1 (en) * | 2014-07-30 | 2016-02-04 | Mochida Pharmaceutical Co., Ltd. | Pyrazole derivative manufacturing method |
| CA2956262A1 (en) * | 2014-07-30 | 2016-02-04 | Mochida Pharmaceutical Co., Ltd. | Pyrazole derivative manufacturing method |
| CN112679467B (zh) | 2015-03-11 | 2024-11-01 | Fmc公司 | 杂环取代的二环唑杀有害生物剂 |
| BR112017019326B1 (pt) | 2015-03-12 | 2022-04-26 | Fmc Corporation | Composto, composição e método para controlar uma praga invertebrada |
| EP3359545B1 (en) | 2015-10-08 | 2024-03-20 | FMC Corporation | Heterocycle-substituted bicyclic azole pesticides |
| ES2932627T3 (es) * | 2017-08-22 | 2023-01-23 | Bayer Ag | Derivados heterocíclicos como pesticidas |
| EP3978077B1 (en) | 2019-05-27 | 2023-11-29 | Nihon Nohyaku Co., Ltd. | Condensed heterocyclic compound having a bridgehead nitrogen atom or salt thereof, agricultural or horticultural insecticide comprising the compound, and method for using the insecticide |
| AR119140A1 (es) | 2019-06-13 | 2021-11-24 | Pi Industries Ltd | Compuestos heterocíclicos fusionados y su uso como agentes de control de plagas |
| CN110396157B (zh) * | 2019-08-07 | 2021-07-30 | 广州市建筑科学研究院有限公司 | 缓释型聚羧酸纳米减水剂及其制备方法和应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011063830A1 (en) | 2009-11-24 | 2011-06-03 | Nokia Corporation | An apparatus |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6355653B1 (en) * | 1999-09-06 | 2002-03-12 | Hoffmann-La Roche Inc. | Amino-triazolopyridine derivatives |
| WO2005012485A2 (en) | 2003-07-31 | 2005-02-10 | Bayer Pharmaceuticals Corporation | Methods for treating diabetes and related disorders using pde10a inhibitors |
| NL2000397C2 (nl) * | 2006-01-05 | 2007-10-30 | Pfizer Prod Inc | Bicyclische heteroarylverbindingen als PDE10 inhibitoren. |
| WO2010035745A1 (ja) * | 2008-09-25 | 2010-04-01 | 杏林製薬株式会社 | ヘテロ環ビアリール誘導体及びそれらを有効成分とするｐｄｅ阻害剤 |
| WO2010059836A1 (en) * | 2008-11-20 | 2010-05-27 | Decode Genetics Ehf | Substituted aza-bridged bicyclics for cardiovascular and cns disease |
| US8685967B2 (en) * | 2009-04-07 | 2014-04-01 | Merck Sharp & Dohme Corp. | Substituted triazolopyridines and analogs thereof |
| HRP20150345T1 (hr) * | 2009-09-24 | 2015-05-08 | F. Hoffmann-La Roche Ag | Derivati imidazopiridina ili imidazopirimidina kao inhibitori fosfodiesteraze 10a |
| TWI485151B (zh) * | 2009-12-17 | 2015-05-21 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族苯基咪唑衍生物 |
| TWI487705B (zh) * | 2009-12-17 | 2015-06-11 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族芳基三唑衍生物 |
| TW201200516A (en) * | 2009-12-17 | 2012-01-01 | Lundbeck & Co As H | Phenylimidazole derivatives comprising an ethynylene linker as PDE10A enzyme inhibitors |
-
2012
- 2012-09-17 PE PE2014000366A patent/PE20141553A1/es not_active Application Discontinuation
- 2012-09-17 PH PH1/2014/500499A patent/PH12014500499A1/en unknown
- 2012-09-17 AU AU2012311713A patent/AU2012311713A1/en not_active Abandoned
- 2012-09-17 BR BR112014006248A patent/BR112014006248A2/pt not_active IP Right Cessation
- 2012-09-17 SG SG11201400759RA patent/SG11201400759RA/en unknown
- 2012-09-17 CA CA2846758A patent/CA2846758C/en not_active Expired - Fee Related
- 2012-09-17 KR KR1020147009588A patent/KR101584925B1/ko not_active Expired - Fee Related
- 2012-09-17 EP EP12759445.5A patent/EP2758396B1/en not_active Not-in-force
- 2012-09-17 UA UAA201404029A patent/UA108711C2/uk unknown
- 2012-09-17 JP JP2014531187A patent/JP2014526533A/ja active Pending
- 2012-09-17 EA EA201490599A patent/EA201490599A1/ru unknown
- 2012-09-17 WO PCT/EP2012/068203 patent/WO2013041472A1/en not_active Ceased
- 2012-09-17 MX MX2014003025A patent/MX2014003025A/es active IP Right Grant
- 2012-09-17 CN CN201280045398.XA patent/CN103827114B/zh not_active Expired - Fee Related
- 2012-09-17 ES ES12759445.5T patent/ES2626801T3/es active Active
-
2014
- 2014-03-05 CO CO14047250A patent/CO6900144A2/es unknown
- 2014-03-06 IL IL231403A patent/IL231403A0/en unknown
- 2014-03-17 CL CL2014000641A patent/CL2014000641A1/es unknown
- 2014-03-18 US US14/218,275 patent/US8946427B2/en not_active Expired - Fee Related
- 2014-12-16 US US14/572,312 patent/US9227970B2/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011063830A1 (en) | 2009-11-24 | 2011-06-03 | Nokia Corporation | An apparatus |
Also Published As
| Publication number | Publication date |
|---|---|
| IL231403A0 (en) | 2014-04-30 |
| UA108711C2 (uk) | 2015-05-25 |
| US20140303141A1 (en) | 2014-10-09 |
| US9227970B2 (en) | 2016-01-05 |
| PH12014500499A1 (en) | 2014-04-14 |
| KR20140075716A (ko) | 2014-06-19 |
| CN103827114B (zh) | 2016-08-24 |
| CL2014000641A1 (es) | 2014-11-14 |
| CN103827114A (zh) | 2014-05-28 |
| CA2846758C (en) | 2017-09-12 |
| EP2758396A1 (en) | 2014-07-30 |
| SG11201400759RA (en) | 2014-07-30 |
| US8946427B2 (en) | 2015-02-03 |
| EP2758396B1 (en) | 2017-03-29 |
| WO2013041472A1 (en) | 2013-03-28 |
| BR112014006248A2 (pt) | 2017-04-11 |
| CA2846758A1 (en) | 2013-03-28 |
| ES2626801T3 (es) | 2017-07-26 |
| CO6900144A2 (es) | 2014-03-20 |
| NZ621597A (en) | 2015-04-24 |
| EA201490599A1 (ru) | 2014-07-30 |
| AU2012311713A1 (en) | 2014-03-13 |
| PE20141553A1 (es) | 2014-10-30 |
| JP2014526533A (ja) | 2014-10-06 |
| MX2014003025A (es) | 2014-05-28 |
| US20150099735A1 (en) | 2015-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101584925B1 (ko) | Pde10a 억제제로서의 트라이아졸로피리딘 화합물 | |
| JP5932828B2 (ja) | トリアゾロピリジン化合物 | |
| TWI478924B (zh) | 咪唑并嘧啶衍生物 | |
| JP5629322B2 (ja) | ホスホジエステラーゼ１０ａ阻害剤としてのイミダゾピリジンまたはイミダゾピリミジン誘導体 | |
| US9150588B2 (en) | Substituted pyridazin-4(1H)-ones as phosphodiesterase 10A inhibitors | |
| EP2574607A1 (en) | PDE10 modulators | |
| HK1193595A (en) | Triazolopyridine compounds as pde10a inhibitors | |
| NZ621597B2 (en) | Triazolopyridine compounds as pde10a inhibitors | |
| JP6471169B2 (ja) | 神経学的障害の処置のための（ヘテロ）アリールイミダゾール類／ピラゾール類 | |
| TW201305155A (zh) | 三唑并吡啶化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| LAPS | Lapse due to unpaid annual fee | ||
| PC1903 | Unpaid annual fee |
St.27 status event code: A-4-4-U10-U13-oth-PC1903 Not in force date: 20190107 Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE |
|
| PC1903 | Unpaid annual fee |
St.27 status event code: N-4-6-H10-H13-oth-PC1903 Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE Not in force date: 20190107 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-5-5-R10-R18-oth-X000 |